1. Type I interferonopathies in pediatric rheumatology.
- Author
-
Volpi S, Picco P, Caorsi R, Candotti F, and Gattorno M
- Subjects
- Aortic Diseases genetics, Aortic Diseases immunology, Arthritis, Juvenile diagnosis, Autoimmune Diseases diagnosis, Autoimmune Diseases genetics, Autoimmune Diseases therapy, Autoimmune Diseases of the Nervous System diagnosis, Autoimmune Diseases of the Nervous System immunology, Dental Enamel Hypoplasia genetics, Dental Enamel Hypoplasia immunology, Homozygote, Humans, Interferon Type I genetics, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic genetics, Lupus Erythematosus, Systemic immunology, Metacarpus abnormalities, Metacarpus immunology, Muscular Diseases genetics, Muscular Diseases immunology, Mutation genetics, Mutation immunology, Nervous System Malformations diagnosis, Nervous System Malformations immunology, Odontodysplasia genetics, Odontodysplasia immunology, Osteochondrodysplasias genetics, Osteochondrodysplasias immunology, Osteoporosis genetics, Osteoporosis immunology, Proteome genetics, Proteome immunology, Rare Diseases diagnosis, Rare Diseases immunology, Rare Diseases therapy, Signal Transduction, Vascular Calcification genetics, Vascular Calcification immunology, Arthritis, Juvenile immunology, Autoimmune Diseases immunology, Interferon Type I immunology
- Abstract
Defective regulation of type I interferon response is associated with severe inflammatory phenotypes and autoimmunity. Type I interferonopathies are a clinically heterogenic group of Mendelian diseases with a constitutive activation of this pathway that might present as atypical, severe, early onset rheumatic diseases. Skin vasculopathy with chilblains and livedo reticularis, interstitial lung disease, and panniculitis are common. Recent studies have implicated abnormal responses to nucleic acid stimuli or defective regulation of downstream effector molecules in disease pathogenesis. As observed for IL1-β and autoinflammatory diseases, knowledge of the defects responsible for type I interferonopathies will likely promote the development of targeted therapy.
- Published
- 2016
- Full Text
- View/download PDF